60 Degrees Pharmaceuticals Suspends Phase IIB Study Of Tafenoquine For COVID-19, Pivots To Refocus On Commercialization Of Treatments For Malaria And Tick-Borne Diseases
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has suspended its Phase IIB study of tafenoquine for COVID-19, following FDA advice that the study may not be feasible in the U.S. The company will now focus on commercializing treatments for malaria and tick-borne diseases, including a Phase IIA study of tafenoquine in hospitalized babesiosis patients. A pre-IND meeting request with the FDA for babesiosis is planned for Q4 2023.
October 12, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
60 Degrees Pharmaceuticals, potentially linked to SXTP, has suspended its COVID-19 study, shifting focus to malaria and tick-borne diseases. This could impact the company's short-term strategy and potential revenue streams.
The suspension of the COVID-19 study could potentially delay any revenue that could have been generated from it. However, the pivot to focus on malaria and tick-borne diseases could open up new revenue streams, depending on the success of these initiatives. The relevance and importance are moderately high due to the potential impact on the company's strategy and revenues.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75